Oral alendronate cannot yet be recommended for children with OI .
This report has been verified
by one or more authors of the
original publication.
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study
J Clin Endocrinol Metab. 2011 Feb;96(2):355-64139 children and adolescents with moderate to severe osteogenesis imperfecta (OI) were randomized to evaluate the safety and efficacy of oral alendronate (ALN). The trial primarily focused on the assessment of lumbar spine bone mineral density (LS BMD) alongside several secondary critera/data: clinical, radiological, biochemical, and multiple bone-related measurements and fracture details. Results demonstrated that ALN, compared to a placebo, effectively increased LS areal BMD z-scores, was adequately tolerated, and efficiently inhibited the activity of bone absorption. However, limited effect of ALN was observed in clinical parameters.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
